Bisphosphonate Bone Metastases Trials Proportion of Patients With Pathologic Fractures§(12, 010)

Pamidronate Study 12:Proportion of patients with pathologic fracture in the 3 mo prior to study entry

Time from diagnosis Without pathologic With pathologicto study entry N fractures, % fractures, %

? 6 mo 115 75 25

> 6 mo 277 90 10

ZOMETAŽ Study 010: Proportion of pamidronate patients with pathologic fracture

Time from diagnosis Patients, % to study entry N 3 mo 6 mo 9 mo 13 mo

? 6 mo 104 21 38 40 45

> 6 mo 62 15 24 32 37

42

§Intent-to treat.

Previous slide

Next slide

Back to first slide

View graphic version